Revelation Biosciences, INC.: management transactions · United States · SEC (Form 4)

About Revelation Biosciences, INC.

Revelation Biosciences, Inc. is a United States-based clinical-stage biotechnology company listed on the NASDAQ Capital Market in the United States. Founded in May 2020, the company has built its strategy around a scientific thesis focused on rebalancing inflammation to optimize health and potentially address both acute and chronic disease. Its operational base is in San Diego, California, a major U.S. life sciences hub that provides access to clinical development talent, scientific infrastructure, and specialist capital markets. From a business perspective, Revelation is not yet a commercial-stage pharmaceutical company. It is primarily a research-and-development organization whose value is driven by its pipeline rather than by product sales. Public filings indicate that the company has devoted most of its resources since inception to corporate setup, financing, research, and the advancement of its product candidates. Its development efforts have centered on clinical programs in renal and inflammatory disease areas, including assets referenced in SEC filings as product candidates for acute kidney injury and chronic kidney disease. For investors, this makes Revelation a classic pipeline-dependent biotech rather than a revenue-generating healthcare platform. In competitive terms, Revelation operates as a small-cap clinical-stage biotech in a highly crowded and capital-intensive market. Its competitive position depends less on scale and more on scientific differentiation, clinical execution, and the ability to generate data that can support future development and, eventually, regulatory pathways. The company competes indirectly with larger pharmaceutical groups, better-capitalized biotechnology peers, and academic translational programs pursuing similar therapeutic themes. As with many early-stage biotechs, valuation is highly sensitive to trial outcomes, financing availability, and dilution risk. Recent company developments highlight that Revelation has continued to rely on capital markets to fund operations. SEC filings from 2025 and 2026 show a continued financing focus, including a public offering announced in May 2025 that generated approximately $4 million in gross proceeds to support clinical and operating needs. Recent quarterly disclosures also emphasize limited cash resources and the ongoing need to raise additional capital, which is a central issue for micro-cap biotech investors. In addition, Form 4 insider transaction filings underscore active monitoring of executive and director share activity, a relevant signal for governance-focused investors. Overall, Revelation Biosciences is a high-risk, high-optionalities health and pharma story on NASDAQ in the United States. Its investment case will likely hinge on clinical progress, data quality, and financing execution rather than on current operating scale or commercial diversification.